Novo Nordisk's shares fell as much as 7% despite the Danish drugmaker setting a $23 billion sales target for its obesity drugs, as it seeks to convince investors it can compete in an increasingly crowded field, according to CNBC.
Key facts
- Novo Nordisk shares fell as much as 7%, according to CNBC.
- The company set a $23 billion sales target for its obesity drugs.
- Novo Nordisk is a Danish pharmaceutical company.
- CNBC described the obesity drug field as increasingly crowded.
- CNBC reported Novo Nordisk helped pioneer the obesity drug field.
Shares in Novo Nordisk fell by as much as 7% despite the Danish drugmaker unveiling a $23 billion sales target for its obesity drugs, according to CNBC.
CNBC reported that the company is seeking to convince investors it can compete in an increasingly crowded field, one it helped pioneer.
Further details of the sales target and the company’s plans were not specified in the available reporting.
Why it matters
Obesity drugs have become one of the most closely watched segments of the pharmaceutical industry. Novo Nordisk's share reaction reflects investor scrutiny of the company's position as competition in the field increases, according to CNBC.
Frequently asked questions
How much did Novo Nordisk stock fall?
According to CNBC, Novo Nordisk shares fell by as much as 7%.
What sales target did Novo Nordisk set for its obesity drugs?
The company set a $23 billion sales target for its blockbuster obesity drugs.
Why is Novo Nordisk under pressure?
Novo Nordisk is trying to convince investors it can compete in an increasingly crowded obesity drug market that it helped pioneer.